Brokerages Expect Cantel Medical Corp. (NYSE:CMD) to Post $0.61 EPS

Cantel Medical Corp. (NYSE:CMD) has earned an average broker rating score of 2.33 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold recommendation and one has given a strong buy recommendation to the company. Cantel Medical’s rating score has improved by 6.8% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Brokerages have set a twelve-month consensus price target of $120.00 for the company and are expecting that the company will post $0.61 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Cantel Medical an industry rank of 70 out of 256 based on the ratings given to its competitors.

NYSE:CMD traded down $3.98 during trading hours on Thursday, hitting $85.02. 633,808 shares of the company traded hands, compared to its average volume of 242,933. The stock has a market capitalization of $3.72 billion, a price-to-earnings ratio of 33.87 and a beta of 1.09. Cantel Medical has a twelve month low of $63.47 and a twelve month high of $99.68. The firm has a 50-day moving average of $88.59 and a 200 day moving average of $76.06. The company has a current ratio of 2.33, a quick ratio of 1.45 and a debt-to-equity ratio of 0.34.

About Cantel Medical

Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Endoscopy segment offers automated endoscope reprocessing systems; infectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets, transport systems, and mobile medical carts; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services.

See Also: What is a stock portfolio tracker?

Get a free copy of the Zacks research report on Cantel Medical (CMD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with's FREE daily email newsletter.